UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  November 23, 2015

 

Bellerophon Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-36845

 

47-3116175

(State or Other Jurisdiction of
Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

184 Liberty Corner Road, Suite 302
Warren, New Jersey

 

07059

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (908) 574-4770

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)                                 On November 23, 2015, each of R. Scott Huennekens and Robert Nelsen notified Bellerophon Therapeutics, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective December 1, 2015. Neither Mr. Huennekens’ nor Mr. Nelsen’s decision to resign from the Board was due to a disagreement on any matter related to the Company’s operations, policies or practices.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BELLEROPHON THERAPEUTICS, INC.

 

 

Date: November 30, 2015

By:

/s/ Jonathan M. Peacock

 

 

 

 

 

Name: Jonathan M. Peacock

Title: Chairman and Chief Executive Officer

 

3